EICHOR

Recruiting studies: Chronic Myeloid Leukaemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-inten
Phase 2 · 10 location(s) · University of Liege · NCT03852407 PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2 · 11 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06409936 Two Step Haplo With Radiation Conditioning
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT05031897 Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
Phase N/A · 5 location(s) · University of Pisa · NCT06119269 Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Ste
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06398457 Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661 Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia
NA · 1 location(s) · Centre Hospitalier Henri Duffaut - Avignon · NCT06082804 International Chronic Myeloid Leukemia Pediatric Study
Phase N/A · 20 location(s) · Poitiers University Hospital · NCT01281735 Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07375355 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054 Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381 Vitamin A and D Supplementation in Allogeneic HCT
Phase 2 · 1 location(s) · St. Petersburg State Pavlov Medical University · NCT06508099 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854 Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 · 5 location(s) · Tr1X, Inc. · NCT06462365 ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 · 1 location(s) · Leland Metheny · NCT06680661 Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Phase 1 · 1 location(s) · Eilean Therapeutics AU Pty Ltd · NCT07527221 A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
Phase 1 · 3 location(s) · City of Hope Medical Center · NCT07020533 The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Phase N/A · 15 location(s) · Peking University People's Hospital · NCT06390306 Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066 Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06013423 ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid L
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05007873 Study of Olverembatinib (HQP1351) in Patients With CP-CML
Phase 3 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06423911 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451 A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06401603 MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225 Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in C
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06236724 Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/Phase 2 · 6 location(s) · Ellipses Pharma · NCT04581512 Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594 Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT00816114 Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Phase N/A · 1 location(s) · Carmen Fava · NCT06724536

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →